JP2013510886A5 - - Google Patents

Download PDF

Info

Publication number
JP2013510886A5
JP2013510886A5 JP2012539076A JP2012539076A JP2013510886A5 JP 2013510886 A5 JP2013510886 A5 JP 2013510886A5 JP 2012539076 A JP2012539076 A JP 2012539076A JP 2012539076 A JP2012539076 A JP 2012539076A JP 2013510886 A5 JP2013510886 A5 JP 2013510886A5
Authority
JP
Japan
Prior art keywords
unsubstituted
substituted
membered
alkyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012539076A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013510886A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/056890 external-priority patent/WO2011060440A2/en
Publication of JP2013510886A publication Critical patent/JP2013510886A/ja
Publication of JP2013510886A5 publication Critical patent/JP2013510886A5/ja
Pending legal-status Critical Current

Links

JP2012539076A 2009-11-16 2010-11-16 キナーゼ阻害剤 Pending JP2013510886A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26169609P 2009-11-16 2009-11-16
US61/261,696 2009-11-16
US33027110P 2010-04-30 2010-04-30
US61/330,271 2010-04-30
PCT/US2010/056890 WO2011060440A2 (en) 2009-11-16 2010-11-16 Kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2013510886A JP2013510886A (ja) 2013-03-28
JP2013510886A5 true JP2013510886A5 (cg-RX-API-DMAC7.html) 2014-01-09

Family

ID=43992477

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012539076A Pending JP2013510886A (ja) 2009-11-16 2010-11-16 キナーゼ阻害剤

Country Status (9)

Country Link
US (2) US20130035325A1 (cg-RX-API-DMAC7.html)
EP (1) EP2558099A4 (cg-RX-API-DMAC7.html)
JP (1) JP2013510886A (cg-RX-API-DMAC7.html)
CN (1) CN102711765A (cg-RX-API-DMAC7.html)
AU (1) AU2010319964A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012011528A2 (cg-RX-API-DMAC7.html)
CA (1) CA2781056A1 (cg-RX-API-DMAC7.html)
MX (1) MX2012005678A (cg-RX-API-DMAC7.html)
WO (1) WO2011060440A2 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012255860C1 (en) 2011-05-17 2015-12-10 Principia Biopharma Inc. Tyrosine kinase inhibitors
WO2012158795A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
DK2710007T3 (da) * 2011-05-17 2020-01-27 Principia Biopharma Inc Kinasehæmmere
CN104487441B (zh) 2012-06-18 2018-06-01 普林斯匹亚生物制药公司 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶
EP2890691B1 (en) 2012-08-31 2018-04-25 Principia Biopharma Inc. Benzimidazole derivatives as itk inhibitors
SMT201900344T1 (it) * 2012-09-10 2019-07-11 Principia Biopharma Inc Composti di pirazolopirimidina come inibitori di chinasi
WO2014093230A2 (en) 2012-12-10 2014-06-19 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN112353806A (zh) 2014-02-21 2021-02-12 普林斯匹亚生物制药公司 Btk抑制剂的盐和固体形式
KR102073797B1 (ko) * 2014-07-07 2020-02-05 지앙수 헨그루이 메디슨 컴퍼니 리미티드 단백질 키나제 저해제로서의 아미노피리다지논 화합물
SG11201704808VA (en) 2014-12-18 2017-07-28 Principia Biopharma Inc Treatment of pemphigus
US20180305350A1 (en) 2015-06-24 2018-10-25 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN106939002B (zh) * 2016-01-05 2019-09-24 江苏恒瑞医药股份有限公司 一种btk激酶抑制剂的结晶形式及其制备方法
ES2875384T3 (es) 2016-01-05 2021-11-10 Jiangsu Hengrui Medicine Co Forma cristalina del inhibidor de la quinasa BTK y método de preparación del mismo
IL263815B (en) 2016-06-29 2022-07-01 Principia Biopharma Inc Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(Oxtan-3-yl)piperazin-1-yl)pent-2-ananitrile
SG10202106949XA (en) 2016-11-18 2021-07-29 Cystic Fibrosis Found Pyrrolopyrimidines as cftr potentiators
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
AU2020365951B2 (en) 2019-10-14 2026-07-16 Principia Biopharma Inc. Methods for treating immune thrombocytopenia by administering (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
KR102993352B1 (ko) 2019-12-20 2026-07-22 프린시피아 바이오파마, 인코퍼레이티드 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-에네니트릴의 고체 형태
WO2021150723A1 (en) 2020-01-22 2021-07-29 Principia Biopharma Inc. Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
CN111205232B (zh) * 2020-02-26 2022-07-01 浙江天宇药业股份有限公司 一种替格瑞洛中间体的合成方法
TW202307005A (zh) 2021-05-28 2023-02-16 美商邊際分析公司 以核醣體蛋白質S6激酶α-1 (RSK1)及核醣體蛋白質S6激酶α-3 (RSK2)之調節劑治療神經病症之方法
CN116332996B (zh) * 2023-05-04 2025-04-01 南京颐媛生物医学研究院有限公司 L-呋喃核糖型抗冠状病毒化合物及其制备方法和应用
CN116284135B (zh) * 2023-05-04 2025-03-21 南京颐媛生物医学研究院有限公司 抗冠状病毒核苷类化合物的制备方法及其应用
CN116410228B (zh) * 2023-05-04 2025-10-31 南京颐媛生物医学研究院有限公司 一种抗冠状病毒核苷类化合物的制备方法及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO811630L (no) * 1980-05-29 1981-11-30 Bayer Ag Imidazoazolalkensyreamider, nye mellomprodukter for deres fremstilling, deres fremstilling og deres anvendelse som legemiddel
DE3216416A1 (de) * 1982-05-03 1983-11-03 Bayer Ag, 5090 Leverkusen Heteroarylthiovinyl-verbindungen, ein verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
DE3502264A1 (de) * 1985-01-24 1986-07-24 Bayer Ag, 5090 Leverkusen Imidazoalkensaeurederivate, ein verfahren zu ihrer herstellung und ihre verwendung fuer die herstellung pharmazeutischer wirkstoffe
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
EP0450073B1 (en) * 1988-12-26 1995-03-08 Zenyaku Kogyo Kabushikikaisha 1-azaindolizine derivative, intermediate for synthesis thereof, and antiallergic containing 1-azaindolizine derivative
GB9004483D0 (en) * 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
JPH05301838A (ja) * 1991-10-15 1993-11-16 Mitsubishi Kasei Corp スチレン誘導体
US5792771A (en) * 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
GB9226855D0 (en) * 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
WO1995024190A2 (en) * 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9406137D0 (en) * 1994-03-28 1994-05-18 Erba Carlo Spa N-substituted beta-aryl- and betaheteroaryl-alpha-cyanoacrylamide derivatives and process for their preparation
GB9412719D0 (en) * 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
US6331555B1 (en) * 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
AU2640999A (en) * 1998-02-26 1999-09-15 Zenyaku Kogyo Kabushiki Kaisha 1-azaindolizine derivatives
JP4727579B2 (ja) * 2003-08-01 2011-07-20 中外製薬株式会社 マロニル−CoAデカルボキシラーゼ阻害剤として有用なシアノアミド化合物
US7807719B2 (en) * 2004-09-14 2010-10-05 Chaim Roifman Compounds useful for modulating abnormal cell proliferation
CA2623327A1 (en) * 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
WO2007115269A2 (en) * 2006-03-31 2007-10-11 The Board Of Regents Of The University Of Texas System Orally bioavailable caffeic acid related anticancer drugs
US7645748B2 (en) 2006-04-03 2010-01-12 Forbes Medi-Tech Inc. Sterol/stanol phosphorylnitroderivatives and use thereof
WO2008005954A2 (en) * 2006-06-30 2008-01-10 The Board Of Regents Of The University Of Texas System Tryphostin-analogs for the treatment of cell proliferative diseases
US8268809B2 (en) * 2006-09-05 2012-09-18 Emory University Kinase inhibitors for preventing or treating pathogen infection and method of use thereof
US20120028981A1 (en) 2008-11-05 2012-02-02 Principia Biopharma Inc. Kinase Knockdown Via Electrophilically Enhanced Inhibitors
US20100113520A1 (en) 2008-11-05 2010-05-06 Principia Biopharma, Inc. Kinase knockdown via electrophilically enhanced inhibitors
US8426428B2 (en) 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors

Similar Documents

Publication Publication Date Title
AU2018226470B2 (en) Compounds for treatment of cancer
ES2959419T3 (es) Formulaciones secas por aspersión
ES2675720T3 (es) Inhibidores de quinasa no selectivos
JP6021805B2 (ja) 腫瘍治療剤
JP2012522003A5 (cg-RX-API-DMAC7.html)
WO2014055996A2 (en) Rho kinase inhibitors
NZ630457A (en) Compounds useful as inhibitors of atr kinase
EA201992082A1 (ru) Ингибитор поверхностного антигена вируса гепатита b
RU2011142182A (ru) Соединения
AR049769A1 (es) Derivados de pirazolo(1,5-a)pirimidin 7-il-amina para utilizarse en el tratamiento de enfermedades dependientes de la quinasa de proteina
SI3106463T1 (en) Substituted pyrazolo(1,5-)pyrimidine compounds as trk kinase inhibitors
WO2017001853A1 (en) Antiviral compounds
JP2012520861A5 (cg-RX-API-DMAC7.html)
CR10419A (es) Derivados de Pirazolo [3,4-D]-Pirimidina útiles para tratar trastornos respiratorios
EP2769722A1 (en) Compounds for use in inhibiting HIV capsid assembly
NZ592608A (en) Benzoxazole kinase inhibitors and methods of use
RU2013141274A (ru) Содержащие фосфор соединения в качестве ингибиторов протеинкиназ
JP2018502101A5 (cg-RX-API-DMAC7.html)
JP2014503567A5 (cg-RX-API-DMAC7.html)
WO2014079232A1 (zh) 7-氧代吡啶并嘧啶类化合物及其药用组合物和应用
JP2021514011A5 (cg-RX-API-DMAC7.html)
EA200800403A1 (ru) Производные n-(гетероарил)-1-гетероарилалкил-1н-индол-2-карбоксамидов, их получение и их применение в терапии
JP2023539754A5 (cg-RX-API-DMAC7.html)
RU2005141447A (ru) Производные 2-замещенных фенил-5, 7-дигидрокарбил-3, 7-дигидропирроло [2, 3-d] пиримидин-4-онов, их получение и фармацевтическое применение
ES2675314T3 (es) Profármacos de ácido fosforamídico de 5-[5-fenil-4-(piridin-2-ilmetilamino) quinazolin-2-il] piridin-3-sulfonamida